Highlights Quoin Pharmaceuticals, Ltd.

Stocks

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/06/2026 BST			5-day change	1st Jan Change
4.570 ^USD	+1.78%		-4.19%	-68.33%

06-04	Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan	MT
06-02	Quoin Pharmaceuticals Submits Ind Application for Qrx003 in Peeling Skin Syndrome	CI

Highlights

06-04	Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan	MT
06-02	Quoin Pharmaceuticals Submits Ind Application for Qrx003 in Peeling Skin Syndrome	CI
05-07	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-28	Quoin Pharmaceuticals Ltd Provides Clinical And Regulatory Update For QRX009 Topical Rapamycin Development Programs	CI
03-26	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-25	Quoin Pharmaceuticals provides clinical and regulatory update from constructive type C meeting with U.S. FDA for QRX003 in Netherton syndrome	RE
03-25	Quoin Pharmaceuticals Ltd. Provides Clinical and Regulatory Update for Qrx003 in Netherton Syndrome	CI
03-11	Quoin Pharmaceuticals Ltd. Announces FDA Grants Fast Track Designation For QRX003 For The Treatment Of Netherton Syndrome	CI
01-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome	CI
01-20	Quoin, Inc. Announces Application for Breakthrough Medicine Designation with the SFDA for QRX003	CI
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI
11-06	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
28/10/25	Quoin Pharmaceuticals Ltd. Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 Month 'Whole Body' Data Update from Ongoing Study	CI
21/10/25	Quoin Pharmaceuticals announces U.S. FDA grants orphan drug designation for QRX003 in Netherton Syndrome	RE
07/08/25	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
26/06/25	Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	CI
24/06/25	Quoin Pharmaceuticals Ltd. Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	CI
24/06/25	Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	CI
22/05/25	Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	CI
22/05/25	Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	MT
14/05/25	Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	CI
13/05/25	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
02/04/25	Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric Patient	CI
25/03/25	Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	CI
13/03/25	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI